Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rPhleum
- Development stage
- Phase 3
- Lead developer
- Allergopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
rPhleum is an investigational recombinant allergen immunotherapy developed by Allergopharma for the treatment of grass pollen-induced allergic rhinoconjunctivitis. It consists of an equimolar cocktail of five recombinant major allergens from *Phleum pratense* (Timothy grass): Phl p 1, Phl p 2, Phl p 5a, Phl p 5b, and Phl p 6. These allergens are adsorbed onto aluminium hydroxide for subcutaneous administration. The drug aims to modulate the IgE-mediated allergic immune response, inducing desensitization and immunological tolerance. Clinical development included the pivotal Phase 3 AMETHYST trial, which evaluated its efficacy and safety in adults and adolescents.
- Other names
- recombinant Phleum pratense allergen cocktailrecombinant grass pollen allergen cocktail
02
Targets
Allergen-specific B-cell receptor (Phl p-specific)TCR (T cell antigen receptor complex)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on rPhleum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rPhleum.